Systemic Sclerosis (Scleroderma) Epidemiology Forecast to 2030: Focus on US, France, Germany, Italy, Spain, UK, and Japan – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Systemic Sclerosis (Scleroderma) – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for SSc in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of SSc. The diagnosed prevalent cases of SSc are segmented by age (18 years and older), sex, subtype (lcSSc and dcSSc), digital vasculopathy (RP and fingertip or DUs), and other internal organ involvement (ILD, PAH, kidney disease, cardiac involvement, gastrointestinal involvement, musculoskeletal involvement, and neuromuscular involvement).

The report also includes SSc cases with comorbid malignancy. The following data describes epidemiology of SSc. In the 7MM, the publisher’s epidemiologists forecast an increase in the diagnosed prevalent cases of SSc from 170,921 cases in 2020 to 187,518 cases in 2030, at an AGR of 0.97% over the forecast period.

Women accounted for more diagnosed prevalent cases of SSc than men in the 7MM and it predominantly affects older adults. These findings are in line with the publisher’s estimates and these trends are reflected in the publisher’s forecast for the diagnosed prevalent cases for the 7MM.

Scope

• The Systemic Sclerosis (SSc) Epidemiology Report provides an overview of the risk factors and global trends of SSc in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of SSc segmented by sex and age (ages 18 years). The diagnosed prevalent cases of SSc are further segmented by subtype (lcSSc and dcSSc), digital vasculopathy (Raynaud’s phenomenon [RP] and fingertip or digital ulcers [DU]), and other internal organ involvement (interstitial lung disease [ILD], pulmonary arterial hypertension [PAH], kidney disease, cardiac involvement, gastrointestinal involvement, musculoskeletal involvement, and neuromuscular involvement). The report also includes SSc cases with comorbid malignancy. The model associated with this report additionally provides diagnosed incident cases and total prevalent cases of SSc segmented by age (?18 years) and sex.
• The SSc epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

• Develop business strategies by understanding the trends shaping and driving the global SSc market.
• Quantify patient populations in the global SSc market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SSc therapeutics in each of the markets covered.
• Understand magnitude of SSc population by subtype, digital vasculopathy, and other internal organ involvement.

Key Topics Covered:

1 Systemic Sclerosis: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 7MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc – 7MM

2.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc by Subtype

2.4.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy

2.4.6 Diagnosed Prevalent Cases of by other Internal Organ Involvement and Comorbidities

2.5 Epidemiological Forecast for Systemic Sclerosis (Scleroderma) (2020-2030)

2.5.1 Diagnosed Prevalent Cases of SSc

2.5.2 Age-Specific Diagnosed Prevalent Cases of SSc

2.5.3 Sex-Specific Diagnosed Prevalent Cases of SSc

2.5.4 Diagnosed Prevalent Cases of SSc by Subtype

2.5.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy

2.5.6 Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement

2.5.7 Diagnosed Prevalent Cases of SSc with Comorbid Malignancy

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/bkgdvk

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900